Opinion

Video

Evolving Treatment Landscape in Prostate Cancer

Author(s):

Matthew Smith, MD, PhD,Brian Helfand, MD, PhD

Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
      Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
      1 expert in this video
      Selecting Between Receptor Pathway Inhibitors for mHSPC
      1 expert in this video
      The Use of Ultra-Low PSA in Specific Patient Profiles
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
      Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
      Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
      Related Content
      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
      June 17th 2025

      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

      Hannah Clarke
      ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      AI-based tool aims to optimize MRI use in prostate cancer diagnosis
      June 12th 2025

      AI-based tool aims to optimize MRI use in prostate cancer diagnosis

      Madhur Nayan, MD, PhD
      "I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
      June 9th 2025

      Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

      Hannah Clarke
      In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
      Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis
      June 6th 2025

      Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis

      Michael S. Cookson, MD, MMHC, FACS
      "As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.
      © 2025 MJH Life Sciences

      All rights reserved.